Venetoclax is a B cell lymphoma 2 (BCL-2)–selective antagonist used to treat chronic
lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML). Although this has …

Undermining transcriptional addiction, the dependence of cancers on selected
transcriptional programs, is critically important for addressing cancers with high unmet …

As a catalytic subunit of the positive transcription elongation factor b (P-TEFb), cyclin-
dependent kinase 9 (CDK9) has been demonstrated to contribute to carcinogenesis. This …

Introduction Epigenetic alterations play crucial roles in diffuse large B-cell lymphoma
(DLBCL). Disturbances in lipid metabolism contribute to tumor progression. However …

Pediatric acute myeloid leukemia (AML) develops from clonal expansion of hematopoietic
precursor cells and is characterized by morphologic and cytomolecular heterogeneity …

In the wake of the development of the concept of cell cycle and its limiting points, cyclin-
dependent kinases (CDKs) are considered to play a central role in regulating cell cycle …

Using a genome-wide CRISPR screen, we identified CDK9, DHODH, and PRMT5 as
synthetic lethal partners with gilteritinib treatment in fms-like tyrosine kinase 3 (FLT3) …

Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically
characterized by the t (11; 14) translocation, resulting in the overexpression of Cyclin D1. In …

Alternative splicing and polyadenylation represent two major steps in pre‐mRNA‐
processing, which ensure proper gene expression and diversification of human …

Inducing cell death by the sphingolipid ceramide is a potential anticancer strategy, but the
underlying mechanisms remain poorly defined. In this study, triggering an accumulation of …